Tyra Biosciences Reports Positive SURF302 Results; Plans Phase 3 In LG IR NMIBC
Tyra Biosciences (TYRA) reported positive Phase 2 results for dabogratinib in LG IR NMIBC, showing 79% ORR and 64% CR rate at 60 mg QD. The company plans Phase 3 studies and further evaluation in the ablative setting. Dabogratinib demonstrated favorable safety and tolerability. TYRA stock is down 31.72% in pre-market trading.
How this was made
The 30-second read
Why it matters
The disclosed efficacy rates could accelerate regulatory engagement and attract partnership interest.
Market read
First report of promising Phase 2 results likely to move TYRA stock and influence related biotech valuations.
What to watch
Small patient cohort (14 evaluable) and lack of long‑term durability data.
Background
Tyra Biosciences is developing dabogratinib, an oral FGFR3‑selective inhibitor for low‑grade bladder and urothelial cancers.
Ticker impact
Tyra Biosciences reported Phase 2 SURF302 data showing 79% ORR and 75% CR at 60 mg QD, a new positive efficacy signal.
upward pressure, potential 10‑15% rally on day of release
First disclosure of robust efficacy in a rare bladder‑cancer indication; investors typically reward such data.
Market effects
Strengthens outlook for FGFR3‑targeted oncology assets and may lift peer biotech valuations.
Positive for US biotech sector; limited global spillover.
Modest, confined to specialty oncology investors.
Counterpoint
Phase 2 data may not translate to Phase 3 success; safety profile still early.
Key entities
- companyTyra Biosciences, Inc.
Biotech firm developing FGFR3‑targeted therapies.
- drugdabogratinib
Investigational oral FGFR3 inhibitor.
